SYSTEMS AND METHODS FOR TREATING DIAGNOSING AND PREDICTING THE OCCURRENCE OF A MEDICAL CONDITION

• US 20100088264A1
• Filed: 04/07/2008
• Published: 04/08/2010
• Est. Priority Date: 04/05/2007
• Status: Abandoned Application

• Current Assignee: Champalimaud Foundation
• Original Assignee: Aureon Biosciences, Inc.
• Inventors: Teverovskiy, Mikhail, Verbel, David A., Saidi, Olivier
• Application Number:
  US12/449,710
• Publication Number:
  US 20100088264A1
• Time in Patent Office: Days
• US Class Current: 706/46
• CPC Class Codes: G16H 50/20 for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Methods and systems are provided that use clinical information, molecular information and computer-generated morphometric information in a predictive model for predicting the occurrence (e.g., recurrence) of a medical condition, for example, cancer. In an embodiment, a model that predicts prostate cancer recurrence is provided, where the model is based on features including one or more (e.g., all) of biopsy Gleason score, seminal vesicle invasion, extracapsular extension, preoperative PSA, dominant prostatectomy Gleason grade, the relative area of AR+ epithelial nuclei, a morphometric measurement of epithelial nuclei, and a morphometric measurement of epithelial cytoplasm. In another embodiment, a model that predicts clinical failure post-prostatectomy is provided, wherein the model is based on features including one or more (e.g., all) of dominant prostatectomy Gleason grade, lymph node invasion status, one or more morphometric measurements of lumen, a morphometric measurement of cytoplasm, and average intensity of AR in AR+/AMACR− epithelial nuclei.

Claims

1. Apparatus for evaluating a risk of prostate cancer recurrence in a patient, the apparatus comprising:

a model predictive of prostate cancer recurrence configured to evaluate a dataset for a patient to thereby evaluate a risk of prostate cancer recurrence in the patient, wherein the model is based on one or more features selected from the following group of features;

biopsy Gleason score;

seminal vesicle invasion;

extracapsular extension;

preoperative PSA;

dominant prostatectomy Gleason grade;

the relative area of AR+ epithelial nuclei;

a morphometric measurement of epithelial nuclei derived from a tissue image; and

a morphometric measurement of epithelial cytoplasm derived from a tissue image.

2. The apparatus of claim 1, wherein the morphometric measurement of epithelial nuclei comprises a measurement of texture of tumor epithelial nuclei.

3. The apparatus of claim 1, wherein the morphometric measurement of epithelial cytoplasm comprises a measurement of texture of tumor epithelial cytoplasm.

4. The apparatus of claim 1, wherein the model is based on two features from the group.

5. The apparatus of claim 1, wherein the model is based on three features from the group.

6. The apparatus of claim 1, wherein the model is based on four features from the group.

7. The apparatus of claim 1, wherein the model is based on five features from the group.

8. The apparatus of claim 1, wherein the model is based on six features from the group.

9. The apparatus of claim 1, wherein the model is based on seven features from the group.

10. The apparatus of claim 1, wherein the model is based on all eight features from the group.

11. The apparatus of claim 1, wherein the model is configured to produce a value indicative of the risk of occurrence of the medical condition in the patient.

12. The apparatus of claim 1, wherein the model is based on the feature of the relative area of AR+ epithelial nuclei, which feature is based on computer analysis of a tissue image showing immunofluorescence.

13. A method of evaluating a risk of prostate cancer recurrence in a patient, the method comprising:

evaluating a dataset for a patient with a model predictive of prostate cancer recurrence, wherein the model is based on one or more features selected from the following group of features;

biopsy Gleason score, seminal vesicle invasion, extracapsular extension, preoperative PSA, dominant prostatectomy Gleason grade, the relative area of AR+ epithelial nuclei, a morphometric measurement of epithelial nuclei derived from a tissue image, and a morphometric measurement of epithelial cytoplasm derived from a tissue image,

thereby evaluating the risk of prostate cancer recurrence in the patient.

14. The method of claim 13, wherein the morphometric measurement of epithelial nuclei comprises a measurement of texture of tumor epithelial nuclei.

15. The method of claim 13, wherein the morphometric measurement of epithelial cytoplasm comprises a measurement of texture of tumor epithelial cytoplasm.

16. The method of claim 13, further comprising outputting a value indicative of the patient'"'"'s risk of prostate cancer recurrence.

17. The method of claim 13, further comprising generating the feature of relative area of AR+ epithelial nuclei based on computer analysis of a tissue image showing immunofluorescence.

18. A computer-readable medium comprising computer executable instructions recorded thereon for performing the method comprising:

evaluating a dataset for a patient with a model predictive of prostate cancer recurrence to thereby evaluate the risk of prostate cancer recurrence in the patient, wherein the model is based on one or more features selected from the following group of features;

biopsy Gleason score, seminal vesicle invasion, extracapsular extension, preoperative PSA, dominant prostatectomy Gleason grade, the relative area of AR+ epithelial nuclei, a morphometric measurement of epithelial nuclei derived from a tissue image, and a morphometric measurement of epithelial cytoplasm derived from a tissue image.

19. Apparatus for evaluating a risk of clinical failure in a patient subsequent to the patient having a radical prostatectomy, the apparatus comprising:

a model predictive of clinical failure configured to evaluate a dataset for a patient to thereby evaluate a risk of clinical failure for the patient, wherein the model is based on one or more features selected from the following group of features;

dominant prostatectomy Gleason grade;

lymph node invasion status;

a morphometric measurement of lumen derived from a tissue image;

a morphometric measurement of cytoplasm derived from a tissue image; and

average intensity of AR in AR+/AMACR−

epithelial nuclei.

20. The apparatus of claim 19, wherein the morphometric measurement of lumen comprises average perimeter length of lumen.

21. The apparatus of claim 19, wherein the morphometric measurement of lumen comprises relative area of lumen.

22. The apparatus of claim 19, wherein the model is based on at least two morphometric measurements of lumen comprising average perimeter length of lumen and relative area of lumen.

23. The apparatus of claim 19, wherein the model is based on the feature of average intensity of AR in AR+/AMACR−

epithelial nuclei, which features is based on computer analysis of a tissue image showing immunofluorescence.

24. The apparatus of claim 19, wherein the model is based on two features from the group.

25. The apparatus of claim 19, wherein the model is based on three features from the group.

26. The apparatus of claim 19, wherein the model is based on four features from the group.

27. The apparatus of claim 19, wherein the model is based on five features from the group.

28. The apparatus of claim 19, wherein the model is configured to produce a value indicative of the risk of clinical failure in the patient.

29. A method of evaluating a risk of clinical failure in a patient subsequent to the patient having a radical prostatectomy, the method comprising:

evaluating a dataset for a patient with a model predictive of clinical failure post-prostatectomy, wherein the model is based on one or more features selected from the following group of features;

dominant prostatectomy Gleason grade, lymph node invasion status, a morphometric measurement of lumen derived from a tissue image, a morphometric measurement of cytoplasm derived from a tissue image, and average intensity of AR in AR+/AMACR−

epithelial nuclei,

thereby evaluating the risk of clinical failure in the patient.

30. The method of claim 29, wherein the morphometric measurement of lumen comprises average perimeter length of lumen.

31. The method of claim 29, wherein the morphometric measurement of lumen comprises relative area of lumen.

32. The method of claim 29, wherein the model is based on at least two morphometric measurements of lumen comprising average perimeter length of lumen and relative area of lumen.

33. The method of claim 29, further comprising outputting a value indicative of the patient'"'"'s risk of clinical failure.

34. The method of claim 29, further comprising generating the feature of average intensity of AR in AR+/AMACR−

epithelial nuclei based on computer analysis of a tissue image showing immunofluorescence.

35. A computer-readable medium comprising computer executable instructions recorded thereon for performing the method comprising:

evaluating a dataset for a patient with a model predictive of clinical failure post-prostatectomy to thereby evaluate the risk of clinical failure in the patient, wherein the model is based on one or more features selected from the following group of features;

dominant prostatectomy Gleason grade, lymph node invasion status, a morphometric measurement of lumen derived from a tissue image, a morphometric measurement of cytoplasm derived from a tissue image, and average intensity of AR in AR+/AMACR−

epithelial nuclei.